Stocktoria
Nexalin Technology, Inc. NXL
Nasdaq · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2022-09-16
Nexalin Technology, Inc. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $301,647 | $168,721 | $110,748 | $1.3M | $144,065 |
| Gross profit | $240,274 | $132,128 | $85,060 | $958,145 | $122,623 |
| R&D expense | $1.1M | $1.2M | $1.9M | $511,000 | $139,000 |
| SG&A expense | $4.4M | $4.2M | $1.9M | $1.5M | $5.2M |
| Operating income | -$8.4M | -$7.8M | -$5.7M | -$1.8M | -$6.0M |
| Interest expense | -$8,240 | -$3,193 | $38,835 | $59,382 | $82,319 |
| Net income | -$8.2M | -$7.6M | -$4.6M | -$1.7M | -$6.1M |
| EPS (diluted) | $-0.50 | $-0.83 | $-0.63 | $-0.30 | — |
| Operating cash flow | -$5.0M | -$3.9M | -$3.8M | -$2.2M | -$1.1M |
| Cash & equivalents | $654,783 | $574,485 | $580,230 | $162,743 | $661,778 |
| Inventory | $131,473 | $174,578 | $156,420 | $154,370 | $31,410 |
| Total assets | $4.6M | $4.2M | $3.6M | $7.4M | $753,698 |
| Total liabilities | $887,333 | $546,694 | $425,281 | $2.0M | $2.4M |
| Shareholders' equity | $3.7M | $3.7M | $3.2M | $5.5M | -$1.7M |
Growth · year-over-year · Revenue CAGR 20.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | +78.8% | +52.3% | -91.6% | +817.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.